S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
S&P 500   3,117.43 (+0.15%)
DOW   27,677.79 (+0.10%)
QQQ   202.43 (+0.51%)
AAPL   265.58 (+1.47%)
FB   199.36 (+0.33%)
MSFT   149.93 (+0.05%)
GOOGL   1,326.96 (+0.61%)
AMZN   1,740.48 (-1.15%)
CGC   18.60 (+1.20%)
NVDA   208.74 (-0.32%)
MU   46.62 (+0.69%)
BABA   200.00 (+3.23%)
GE   10.79 (-1.01%)
TSLA   330.37 (-0.80%)
T   38.19 (+0.24%)
AMD   39.62 (-0.18%)
ACB   2.44 (-1.61%)
F   8.93 (-0.22%)
PRI   134.30 (+0.83%)
NFLX   302.86 (-0.48%)
BAC   33.09 (-0.18%)
GILD   65.93 (-1.23%)
DIS   147.44 (-0.57%)
Log in

CVE:LBL - Lattice Biologics Stock Price, Forecast & News

C$0.03
0.00 (0.00 %)
(As of 12/5/2019 04:00 PM ET)
Today's Range
C$0.03
Now: C$0.03
C$0.03
50-Day Range
C$0.02
MA: C$0.03
C$0.03
52-Week Range
C$0.01
Now: C$0.03
C$0.05
Volume650,000 shs
Average Volume295,972 shs
Market CapitalizationC$2.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The company offers AmnioBoost, an allograft amniotic fluid visco supplement for the treatment of joint pain associated with osteoarthritis, as well as traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-2356701

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$1.94 million
Book ValueC($0.06) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$2.80 million
Next Earnings Date2/4/2020 (Estimated)
OptionableNot Optionable

Receive LBL News and Ratings via Email

Sign-up to receive the latest news and ratings for LBL and its competitors with MarketBeat's FREE daily newsletter.


Lattice Biologics (CVE:LBL) Frequently Asked Questions

What is Lattice Biologics' stock symbol?

Lattice Biologics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LBL."

When is Lattice Biologics' next earnings date?

Lattice Biologics is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Lattice Biologics.

Has Lattice Biologics been receiving favorable news coverage?

Media coverage about LBL stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Lattice Biologics earned a news impact score of 1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Lattice Biologics.

Who are some of Lattice Biologics' key competitors?

What other stocks do shareholders of Lattice Biologics own?

Who are Lattice Biologics' key executives?

Lattice Biologics' management team includes the folowing people:
  • Mr. Guy S. Cook, CEO, Pres & Director (Age 54)

How do I buy shares of Lattice Biologics?

Shares of LBL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Lattice Biologics' stock price today?

One share of LBL stock can currently be purchased for approximately C$0.03.

How big of a company is Lattice Biologics?

Lattice Biologics has a market capitalization of C$2.80 million and generates C$1.94 million in revenue each year. View Additional Information About Lattice Biologics.

What is Lattice Biologics' official website?

The official website for Lattice Biologics is http://www.latticebiologics.com/.

How can I contact Lattice Biologics?

Lattice Biologics' mailing address is 16701 N 90th St Ste 101, SCOTTSDALE, AZ 85260-1012, United States. The company can be reached via phone at +1-604-2356701.


MarketBeat Community Rating for Lattice Biologics (CVE LBL)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  120
MarketBeat's community ratings are surveys of what our community members think about Lattice Biologics and other stocks. Vote "Outperform" if you believe LBL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LBL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Featured Article: What is the CAC 40 Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel